Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas

A tissue microarray and pooled literature review study

Shi Wei, Nasser Said-Al-Naief, Omar Hameed

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Given their frequent expression in breast and gynecologic carcinomas, the National Comprehensive Cancer Network has recommended that the immunohistochemical expression of estrogen (ER) and/or progesterone (PR) receptors in a carcinoma of unknown primary can be used to support a breast or gynecologic origin. Several reports in the literature, however, have described such expression in a variable proportion of nonmammary and nongynecologic carcinomas. The aim of this study was to systematically evaluate the immunohistochemical expression of ER and PR on tissue microarray sections representing 348 nonbreast or gynecologic and nongynecologic tumors of lung, esophageal, gastric, pancreatic, colonic, renal, or bladder origin. We also performed a pooled analysis of the published literature in this regard. Except for 1 (2.5%) out of 40 pancreatic adenocarcinomas that expressed PR, there was no ER or PR expression in any of the other tumors evaluated by immunohistochemistry. A pooled literature review demonstrated that most of the evaluated tumors express ER and/or PR in up to 3% of cases, whereas some lung and bladder carcinomas showed such expression in around 10% of cases. This literature review also demonstrated that the frequency of ER and PR expression was dependent on the antibody clone used. Given that ER and PR expression can occasionally be seen in carcinomas of nonmammary/nongynecologic origin, we conclude that the diagnosis of metastatic breast, ovarian or endometrial carcinoma in a carcinoma of unknown primary should not be based solely on such expression.

Original languageEnglish (US)
Pages (from-to)393-402
Number of pages10
JournalApplied Immunohistochemistry and Molecular Morphology
Volume17
Issue number5
DOIs
StatePublished - Oct 2009
Externally publishedYes

Fingerprint

Progesterone Receptors
Estrogen Receptors
Progesterone
Breast Neoplasms
Estrogens
Carcinoma
Neoplasms
Urinary Bladder
Lung
Endometrial Neoplasms
Stomach
Adenocarcinoma
Breast
Clone Cells
Immunohistochemistry
Kidney
Antibodies

Keywords

  • Carcinoma
  • Estrogen receptor
  • Immunohistochemistry
  • Progesterone receptor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology
  • Histology

Cite this

@article{f045b8f4d8c64a908b979315172e98de,
title = "Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas: A tissue microarray and pooled literature review study",
abstract = "Given their frequent expression in breast and gynecologic carcinomas, the National Comprehensive Cancer Network has recommended that the immunohistochemical expression of estrogen (ER) and/or progesterone (PR) receptors in a carcinoma of unknown primary can be used to support a breast or gynecologic origin. Several reports in the literature, however, have described such expression in a variable proportion of nonmammary and nongynecologic carcinomas. The aim of this study was to systematically evaluate the immunohistochemical expression of ER and PR on tissue microarray sections representing 348 nonbreast or gynecologic and nongynecologic tumors of lung, esophageal, gastric, pancreatic, colonic, renal, or bladder origin. We also performed a pooled analysis of the published literature in this regard. Except for 1 (2.5{\%}) out of 40 pancreatic adenocarcinomas that expressed PR, there was no ER or PR expression in any of the other tumors evaluated by immunohistochemistry. A pooled literature review demonstrated that most of the evaluated tumors express ER and/or PR in up to 3{\%} of cases, whereas some lung and bladder carcinomas showed such expression in around 10{\%} of cases. This literature review also demonstrated that the frequency of ER and PR expression was dependent on the antibody clone used. Given that ER and PR expression can occasionally be seen in carcinomas of nonmammary/nongynecologic origin, we conclude that the diagnosis of metastatic breast, ovarian or endometrial carcinoma in a carcinoma of unknown primary should not be based solely on such expression.",
keywords = "Carcinoma, Estrogen receptor, Immunohistochemistry, Progesterone receptor",
author = "Shi Wei and Nasser Said-Al-Naief and Omar Hameed",
year = "2009",
month = "10",
doi = "10.1097/PAI.0b013e31819faa07",
language = "English (US)",
volume = "17",
pages = "393--402",
journal = "Applied Immunohistochemistry",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas

T2 - A tissue microarray and pooled literature review study

AU - Wei, Shi

AU - Said-Al-Naief, Nasser

AU - Hameed, Omar

PY - 2009/10

Y1 - 2009/10

N2 - Given their frequent expression in breast and gynecologic carcinomas, the National Comprehensive Cancer Network has recommended that the immunohistochemical expression of estrogen (ER) and/or progesterone (PR) receptors in a carcinoma of unknown primary can be used to support a breast or gynecologic origin. Several reports in the literature, however, have described such expression in a variable proportion of nonmammary and nongynecologic carcinomas. The aim of this study was to systematically evaluate the immunohistochemical expression of ER and PR on tissue microarray sections representing 348 nonbreast or gynecologic and nongynecologic tumors of lung, esophageal, gastric, pancreatic, colonic, renal, or bladder origin. We also performed a pooled analysis of the published literature in this regard. Except for 1 (2.5%) out of 40 pancreatic adenocarcinomas that expressed PR, there was no ER or PR expression in any of the other tumors evaluated by immunohistochemistry. A pooled literature review demonstrated that most of the evaluated tumors express ER and/or PR in up to 3% of cases, whereas some lung and bladder carcinomas showed such expression in around 10% of cases. This literature review also demonstrated that the frequency of ER and PR expression was dependent on the antibody clone used. Given that ER and PR expression can occasionally be seen in carcinomas of nonmammary/nongynecologic origin, we conclude that the diagnosis of metastatic breast, ovarian or endometrial carcinoma in a carcinoma of unknown primary should not be based solely on such expression.

AB - Given their frequent expression in breast and gynecologic carcinomas, the National Comprehensive Cancer Network has recommended that the immunohistochemical expression of estrogen (ER) and/or progesterone (PR) receptors in a carcinoma of unknown primary can be used to support a breast or gynecologic origin. Several reports in the literature, however, have described such expression in a variable proportion of nonmammary and nongynecologic carcinomas. The aim of this study was to systematically evaluate the immunohistochemical expression of ER and PR on tissue microarray sections representing 348 nonbreast or gynecologic and nongynecologic tumors of lung, esophageal, gastric, pancreatic, colonic, renal, or bladder origin. We also performed a pooled analysis of the published literature in this regard. Except for 1 (2.5%) out of 40 pancreatic adenocarcinomas that expressed PR, there was no ER or PR expression in any of the other tumors evaluated by immunohistochemistry. A pooled literature review demonstrated that most of the evaluated tumors express ER and/or PR in up to 3% of cases, whereas some lung and bladder carcinomas showed such expression in around 10% of cases. This literature review also demonstrated that the frequency of ER and PR expression was dependent on the antibody clone used. Given that ER and PR expression can occasionally be seen in carcinomas of nonmammary/nongynecologic origin, we conclude that the diagnosis of metastatic breast, ovarian or endometrial carcinoma in a carcinoma of unknown primary should not be based solely on such expression.

KW - Carcinoma

KW - Estrogen receptor

KW - Immunohistochemistry

KW - Progesterone receptor

UR - http://www.scopus.com/inward/record.url?scp=70349728696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349728696&partnerID=8YFLogxK

U2 - 10.1097/PAI.0b013e31819faa07

DO - 10.1097/PAI.0b013e31819faa07

M3 - Article

VL - 17

SP - 393

EP - 402

JO - Applied Immunohistochemistry

JF - Applied Immunohistochemistry

SN - 1541-2016

IS - 5

ER -